Danmir Therapeutics, LLC is an emerging biopharmaceutical company based in Haverford Township, PA, specializing in the development of novel therapeutics for chronic obstructive pulmonary disease (COPD) and chronic cough. Their lead drug-candidate, DT-0111, is a selective P2X2 3R antagonist that aims to provide a new treatment approach for these respiratory conditions.
With a focus on manipulating P2 receptors' signal transductions activated by extracellular adenosine 5'-triphosphate (ATP), Danmir Therapeutics aims to address the growing global prevalence of COPD and chronic cough, which significantly impact patients' quality of life. Led by founder and internationally recognized expert, Dr. Amir Pelleg, the company is dedicated to developing innovative therapies to improve patient outcomes in these respiratory disorders.
Generated from the website